Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
Last trade$7.61
Day change+$0.515 (+7.26%)
Day range$7.23 – $7.74
Volume2,016,972
Market cap$651M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$651.42M
Price / earnings
—
Price / book
36.27×
Price / sales
8.21×
EV / sales
7.61×
EV / EBITDA
-2.15×
Profitability
Earnings per share
-$3.19
Return on assets
-51.7%
Return on equity
-1,630.7%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.55×
Current ratio
3.6×
Quick ratio
3.56×
Cash ratio
0.39×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$89.12M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KURA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$22.84M
$20.87M
$18.27M
$17.34M
$20.75M
$15.29M
$14.11M
$53.88M
Cost of revenue
$371K
$243K
$262K
$57K
$0
$0
$0
$0
Gross profit
$22.47M
$20.63M
$18M
$17.28M
$20.75M
$15.29M
$14.11M
$53.88M
Selling, general and administrative
$30.25M
$31.75M
$31.56M
$39.14M
$32.84M
$25.17M
$22.84M
$24.07M
Research and development
$66.88M
$61.89M
$65.26M
$64.41M
$67.91M
$62.79M
$55.97M
$52.27M
Total operating expenses
$66.54M
$93.64M
$96.82M
$103.55M
$100.75M
$87.95M
$78.81M
$76.34M
Operating income
-$44.07M
-$73.01M
-$78.82M
-$86.27M
-$80M
-$72.67M
-$64.7M
-$22.46M
Interest expense
-$350K
-$345K
-$336K
-$346K
-$393K
-$391K
-$382K
-$403K
Income before taxes
-$70.22M
-$68.32M
-$73.33M
-$80.93M
-$74.12M
-$66.12M
-$57.2M
-$17.2M
Income taxes
$0
$5K
$8K
$71K
$0
$0
$226K
$2.02M
Net income
-$70.22M
-$68.33M
-$73.33M
-$81M
-$74.12M
-$66.12M
-$57.43M
-$19.22M
Net income attributable to common shareholders
-$70.22M
-$68.33M
-$73.33M
-$81M
-$74.12M
-$66.12M
-$57.43M
-$19.22M
EBITDA
-$43.74M
-$72.64M
-$78.46M
-$85.87M
-$79.83M
-$72.44M
-$64.46M
-$22.25M
Basic earnings per share
-$0.78
-$0.77
-$0.83
-$0.92
-$0.85
-$0.75
-$0.66
-$0.22
Diluted earnings per share
-$0.78
-$0.77
-$0.83
-$0.92
-$0.85
-$0.75
-$0.66
-$0.22
Recent news
Company coverage with links to the original publishers.
Kura Oncology reported a quarterly loss of $0.78 per share, beating the consensus estimate of $0.83 loss, with revenues of $22.84 million exceeding expectations by 2.87%. Despite the earnings beat, the stock has declined 27.1% year-to-date versus the S&P 500's 10.3% gain. The company holds a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.
Septerna, Inc. (SEPN) reported a quarterly loss of $0.57 per share, missing consensus estimates of $0.55, and posted revenues of $18.88 million, falling 19.52% short of expectations. The company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions, with shares expected to underperform the market in the near term despite gaining 75.2% year-to-date.
Qiagen is expected to report Q3 2026 earnings on November 4 with a consensus EPS estimate of $0.63 (down 1.6% YoY) and revenues of $539.44 million (up 1.3% YoY). With a positive Earnings ESP of +4.00% and Zacks Rank #2 (Buy), the company appears positioned to beat consensus estimates. The stock has beaten EPS estimates in 3 of the last 4 quarters.
Kura Oncology is expected to report a quarterly loss of $0.83 per share with revenues of $22.2 million for Q3 2026. While the company has a positive Earnings ESP of +3.61%, its Zacks Rank of #4 (Sell) makes it difficult to predict an earnings beat. The combination of these factors suggests KURA is not a compelling earnings-beat candidate.
Kura Oncology (KURA) shares gained 37.6% over the past month, driven by strong commercial momentum for its lead product Komzifti (ziftomenib), which achieved $9.1 million in Q2 2026 revenues with 57% sequential growth. The company expects multiple data readouts in 2026 and has $519 million in cash to support pipeline execution, with potential expansion of ziftomenib into earlier AML treatment lines and darlifarnib development in solid tumors.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.